Related Experiment Video

Updated: May 24, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas

Sophia Rangwala1, Chunlei Zhang, Madeleine Duvic

  • 1Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Future Medicinal Chemistry
|March 16, 2012
PubMed

Insights

Histone deacetylase inhibitors (HDAC-Is) show promise for cutaneous T-cell lymphoma (CTCL). Overcoming resistance to these epigenetic drugs is key to improving patient response and treatment sustainability.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Small-molecule histone deacetylase inhibitors (HDAC-Is) represent a novel antineoplastic strategy for hematological and solid tumors.
  • Cutaneous T-cell lymphoma (CTCL) is a malignancy where HDAC-Is have shown particular promise, leading to FDA approval of vorinostat and romidepsin for relapsed/refractory cases.

Purpose of the Study:

  • To review the molecular mechanisms of HDAC-inhibitor action in cancer.
  • To discuss the clinical efficacy, side effects, and resistance patterns observed in CTCL patients treated with HDAC-Is.
  • To explore strategies for overcoming HDAC-inhibitor resistance, including combination therapies and biomarker identification.

Main Methods:

  • Literature review of preclinical and clinical studies on HDAC inhibitors in cancer, with a focus on CTCL.
  • Analysis of molecular pathways targeted by HDAC inhibitors.
  • Examination of clinical trial data regarding response rates, durability, and adverse events.
  • Review of research on biomarkers for predicting response and resistance.
  • Assessment of emerging combination therapies aimed at enhancing HDAC inhibitor efficacy.

Main Results:

  • HDAC inhibitors modulate gene expression through epigenetic modifications, impacting cancer cell proliferation, differentiation, and apoptosis.
  • Approved HDAC inhibitors (vorinostat, romidepsin) demonstrate efficacy in relapsed/refractory CTCL, but response rates are suboptimal for many patients.
  • Patient response to HDAC inhibitors can be transient, and resistance mechanisms limit long-term clinical benefit.
  • Identification of potential biomarkers for response and resistance is ongoing.
  • Combination strategies are being investigated to improve therapeutic outcomes.

Conclusions:

  • HDAC inhibitors are a valuable therapeutic class for CTCL, but challenges related to response rates and resistance persist.
  • Further research into biomarkers and synergistic combination therapies is crucial to maximize the clinical potential of HDAC inhibitors in CTCL.
  • Developing strategies to overcome resistance is essential for improving patient outcomes and achieving sustainable responses.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...